Clinical Evidence

With 500+ peer-reviewed publications, HeartFlow is committed to ongoing clinical research as we work to transform the diagnosis and management of coronary artery disease worldwide. Among many benefits, The HeartFlow Analysis is considered to be a “dominant strategy” compared to stress testing as it is “both less costly and more effective.”1

Understand the significant body of research supporting use of the HeartFlow Analysis and its impact to patient care by clicking one of these key areas of research:

Clinical Validity and Accuracy

Clinical Efficacy and Utility

Long Term Patient Safety

Cost Savings

Clinical Validity and Accuracy

The HeartFlow Analysis combines anatomic and physiologic information in a single non-invasive cardiac test that provides clinicians with higher diagnostic performance and accuracy than other non-invasive tests.2

Diagnostic accuracy:

  • 87% (PACIFIC, JACC 2019)

  • 86% (NXT, JACC 2014)3

P-values reflect comparison to the HeartFlow FFRCT Analysis

Long Term Patient Safety

Multiple clinical trials demonstrate that physicians can efficiently determine the most appropriate treatment pathway for each patient by utilizing the HeartFlow Analysis.

There are numerous studies providing long-term follow-up (1-5 years) of over 6,000 patients demonstrating that clinicians can safely and confidently utilize the HeartFlow Analysis in their clinical decision making.

Long Term Outcomes Findings

Patients with a stenosis between 30 and 90% but a negative HeartFlow Analysis (FFRCT > 0.80) have a favorable long-term prognosis with very low rates of adverse cardiac event rates or unplanned revascularization, rates similar to patients without stenosis.8

Among patients with a positive HeartFlow Analysis (FFRCT ≤ 0.80), those who undergo revascularization have lower event rates than patients who do not undergo revascularization.8

Cost Savings

A patient pathway driven by a coronary CTA and appropriate use of the HeartFlow Analysis improves patient care, improves outcomes and lowers the costs of care by providing significant per-patient cost savings.1,5 Importantly, a CTA plus HeartFlow strategy may present a more favorable initial diagnostic option in the evaluation of low-risk stable chest pain compared with stress testing as it provides:


6 months of longer life in perfect health
Better identification of patients needing treatment
50% increase in cath lab yield


Decreased total costs: 10% vs stress testing in all comers population
Long-term cost effectiveness

When evaluating costs of using a CT+HeartFlow pathway compared to diagnostic ICA, cost savings increased5:

For more information about our ongoing research, visit our Clinical Research page.


  1. Karády, et al. JAMA Open. 2020.
  2. Driessen, et al. J Am Coll Cardiol 2019.
  3. Ihdayhid, et al. Radiology 2019.
  4. Fairbairn, et al. Euro Heart J 2018.
  5. Douglas, et al. J Am Coll Cardiol 2016.
  6. Fairbairn, et al. Euro Heart J 2018. Patel, et al, J Am Coll Cardiol Img 2019.
  7. Patel, et al, J Am Coll Cardiol Img 2019.
  8. Nørgaard, et al. J Am Coll Cardiol 2018.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.